(i) Before the CCI and the Competition Appellate Tribunal on the participation in bids to supply meningitis vaccines to the DADG; and (ii) on securing unconditional CCI approval for its proposed internal restructuring through a demerger of GSK CH HoldCo and a series of share exchanges by Pfizer and GSK/GSK affiliates for shares in Haleon.